Dec 2015 $2 M No. 5 $2 to $10 million 28
Diffusion Pharmaceuticals LLC: Raise no. 5, Dec 2015 × Investors in this round 28 investors had bought by the notice of Dec 22, 2015: 28 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $5 M offered; $3 M still to sell
Smallest investment taken $5,000
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the issuer at a conversion price of $2.00 per unit. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Virginia People named in the notice Ben L. Shealy · Executive Officer David G. Kalergis · Executive Officer, Director David R. Jones · Executive Officer John L. Gainer · Executive Officer, Director Alan R. Levin · Director Mark T. Giles · Director Robert W. Adams · Director Thomas E. Byrne · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”Signed by Ben L. Shealy, Senior Vice President - Finance and Treasurer. Source: SEC Form D, newest notice filed Dec 22, 2015. Read the notice at the SEC .
debt, options SEC Jun 2014 $3 M No. 4 $2 to $10 million 30
Diffusion Pharmaceuticals LLC: Raise no. 4, Jun 2014 × Investors in this round 30 investors had bought by the notice of Sep 4, 2014: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the Company at a conversion price of $1.50 per unit. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Virginia People named in the notice Ben L. Shealy · Executive Officer David G. Kalergis · Executive Officer, Director David R. Jones · Executive Officer John L. Gainer · Executive Officer, Director Mark T. Giles · Director Robert W. Adams · Director Thomas E. Byrne · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”Signed by Ben L. Shealy, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 4, 2014. Read the notice at the SEC .
debt, options SEC May 2013 $5 M No. 3 $2 to $10 million 19
Diffusion Pharmaceuticals LLC: Raise no. 3, May 2013 × Investors in this round 19 investors had bought by the notice of Jun 21, 2013: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the Company at a conversion price of $1.25 per unit.
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Virginia People named in the notice Ben L. Shealy · Executive Officer David G. Kalergis · Executive Officer, Director John L. Gainer · Executive Officer, Director Kim L. Whitten · Executive Officer Mark T. GIles · Director Robert W. Adams · Director Thomas E. Byrne · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”Signed by Ben L. Shealy, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed Jun 21, 2013. Read the notice at the SEC .
debt, options SEC Sep 2012 $5 M No. 2 $2 to $10 million 34
Diffusion Pharmaceuticals LLC: Raise no. 2, Sep 2012 × Investors in this round 34 investors had bought by the notice of Oct 1, 2012: 34 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $6 M offered; $1 M still to sell
Smallest investment taken $5,000
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the Company at a conversion price of $1.00 per unit.
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Virginia People named in the notice Ben L. Shealy · Executive Officer David G. Kalergis · Executive Officer, Director John L. Gainer · Executive Officer, Director Kim L. Whitten · Executive Officer Matthew W. Hantzmon · Executive Officer Mark T. Giles · Director Robert W. Adams · Director Thomas E. Byrne · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”Signed by Ben L. Shealy, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed Oct 1, 2012. Read the notice at the SEC .
debt, options SEC Jul 2009 $2 M No. 1 Under $2 million 14
Diffusion Pharmaceuticals LLC: Raise no. 1, Jul 2009 × Investors in this round 14 investors had bought by the notice of Aug 26, 2009: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $5 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $425,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Virginia People named in the notice Ben L. Shealy · Executive Officer David Kalergis · Executive Officer, Director Matthew Hantzmon · Executive Officer Thomas E. Byrne · Executive Officer, Director John L. Gainer · Director Mark T. Giles · Director Robert W. Adams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David G. Kalergis, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 26, 2009. Read the notice at the SEC .
equity SEC